
Evolocumab was associated with a 20% lower risk of fatal or nonfatal myocardial infarction than ezetimibe among more than 544 000 adults with ASCVD.
A Swedish analysis has identified 5 diabetic "clusters" that could aid diagnosis and individualize treatment. Scroll through our quick slideshow for details.






